Holocene Advisors LP Sells 9,616 Shares of Insmed, Inc. $INSM

Holocene Advisors LP trimmed its position in shares of Insmed, Inc. (NASDAQ:INSM) by 0.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,016,806 shares of the biopharmaceutical company’s stock after selling 9,616 shares during the period. Holocene Advisors LP owned 0.95% of Insmed worth $202,971,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently added to or reduced their stakes in INSM. ORG Partners LLC increased its stake in shares of Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 196 shares during the last quarter. Hilltop National Bank bought a new position in Insmed during the second quarter worth about $28,000. FNY Investment Advisers LLC acquired a new position in Insmed during the second quarter worth approximately $33,000. LRI Investments LLC acquired a new position in Insmed during the second quarter worth approximately $59,000. Finally, EverSource Wealth Advisors LLC raised its stake in Insmed by 65.6% in the second quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 263 shares during the period.

Insmed Trading Up 0.9%

Shares of Insmed stock opened at $197.01 on Friday. The firm has a 50-day moving average of $185.10 and a 200-day moving average of $138.91. The stock has a market cap of $42.02 billion, a PE ratio of -31.83 and a beta of 1.01. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $212.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.34 and a current ratio of 4.63.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million for the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative return on equity of 183.55% and a negative net margin of 264.83%.Insmed’s revenue was up 52.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.27) earnings per share. As a group, sell-side analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Insider Buying and Selling at Insmed

In related news, Director Leo Lee sold 75,000 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $195.90, for a total value of $14,692,500.00. Following the completion of the sale, the director directly owned 54,677 shares in the company, valued at approximately $10,711,224.30. The trade was a 57.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Elizabeth M. Anderson sold 5,000 shares of the stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $204.58, for a total value of $1,022,900.00. Following the sale, the director directly owned 58,729 shares in the company, valued at $12,014,778.82. This represents a 7.85% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 147,130 shares of company stock valued at $28,480,051 in the last three months. Corporate insiders own 3.00% of the company’s stock.

Analyst Upgrades and Downgrades

INSM has been the subject of several research analyst reports. Rothschild & Co Redburn started coverage on Insmed in a research note on Thursday, December 4th. They set a “buy” rating and a $263.00 target price for the company. UBS Group raised their price target on Insmed from $194.00 to $223.00 and gave the company a “buy” rating in a report on Friday, October 31st. Cantor Fitzgerald began coverage on shares of Insmed in a research report on Tuesday, October 28th. They set an “overweight” rating and a $192.00 price objective for the company. Morgan Stanley increased their price objective on shares of Insmed from $126.00 to $144.00 and gave the company an “equal weight” rating in a research report on Thursday, August 21st. Finally, Rothschild Redb raised shares of Insmed to a “strong-buy” rating in a report on Thursday, December 4th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $196.26.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.